Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isotretinoin + vorinostat
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of isotretinoin (cis-13-retinoic acid), a retinoid, and vorinostat, a histone deacetylase (HDAC) inhibitor. Preclinical studies demonstrated that vorinostat combined with retinoids produces additive antitumor effects in neuroblastoma. The combination works through complementary mechanisms, with vorinostat inhibiting histone deacetylases, leading to increased histone acetylation and altered gene expression, while isotretinoin acts through retinoid receptors to influence cell differentiation and growth.
- Other names
- suberoylanilide hydroxamic acidisotretinoin
02
Targets
HDAC (HDAC family)RARA (Retinoic acid receptor alpha)RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on isotretinoin + vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isotretinoin + vorinostat.